MZE829 - (HORIZON)

October 6, 2026: Maze Therapeutics (NASDAQ: MAZE) said it will present data on two kidney disease programs at ASN Kidney Week in Denver on October 21–25, 2026.

MZE829 / HORIZON: An oral presentation on October 24, 2026 will provide additional details from previously reported Phase 2 HORIZON data for MZE829 in adults with APOL1-mediated kidney disease (AMKD). The company said the earlier HORIZON results showed encouraging clinical activity, and the ASN presentation is titled “Evaluation of Safety, Tolerability, and Efficacy of MZE829 in Adults with APOL1-Mediated Kidney Disease.”

MZE782 / SLC6A19 inhibition: Two preclinical posters will be presented supporting SLC6A19 inhibition as a potential approach in chronic kidney disease. One poster, on October 23, 2026, focuses on reducing uptake of nephrotoxins to limit kidney injury. A second poster, on October 22, 2026, describes SLC6A19 inhibition driving a protective proximal tubule metabolic state complementary to SGLT2 inhibition.

The announcement is a conference presentation catalyst rather than new clinical data disclosure, with the key upcoming events being the ASN presentations on October 22, 23, and 24, 2026.